secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001140361-24-002915
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna receives Nasdaq non-compliance notice over board independence; has 45 days to submit plan
--------------------------------------------------------------------------------

- Received Nasdaq notice on Jan 17, 2024 for failing majority independent board and audit committee rules under Listing Rule 5605.
- Triggered by appointment of Dorothy Clarke as GC and her resignation from board committees, plus Sanjeev Luther joining board.
- Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- No immediate effect on listing; common stock continues trading under symbol ERNA.
- Company is evaluating director candidates to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036124002915/0001140361-24-002915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036124002915/ef20019104_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-002915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer